MX2019015589A - Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. - Google Patents
Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular.Info
- Publication number
- MX2019015589A MX2019015589A MX2019015589A MX2019015589A MX2019015589A MX 2019015589 A MX2019015589 A MX 2019015589A MX 2019015589 A MX2019015589 A MX 2019015589A MX 2019015589 A MX2019015589 A MX 2019015589A MX 2019015589 A MX2019015589 A MX 2019015589A
- Authority
- MX
- Mexico
- Prior art keywords
- inflammation
- tissue
- hypoxia
- expression
- factors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La invención se refiere a vectores de expresión de ADN, polinucleotídicos sintéticos de ADN capaces de expresar transgenes, tales como factores de curación, en sitios de tejido dañado, para su uso en la promoción de la reparación de heridas y la regeneración de tejidos. Los vectores incluyen un potenciador sintético autorregulado por hipoxia y/o inflamación, que promueve la expresión de agentes proteicos internos, con actividad terapéutica de manera dependiente del daño. Los vectores de expresión de ADN de la invención son de utilidad para promover la producción aumentada de proteínas recombinantes con propiedades biológicas, en una pluralidad de sistemas de expresión eucarióticos. Los vectores descritos pueden usarse para promover la curación y la regeneración de tejido dañado, incluyendo corazón, intestino, riñón, hígado, pulmón, tejido conectivo articulaciones piel, y/o para detectar tejido lesionado o dañado mediante la expresión de factores reporteros que funcionan como marcadores diagnósticos o mediante la expresión de factores de regeneración de tejido o cicatrización de heridas para tratar, prevenir y mejorar las enfermedades por inflamación crónica severa y fibrosis que padecen los humanos, como la fibrosis del hígado, los riñones o el páncreas y la artritis reumatoide.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019015589A MX2019015589A (es) | 2019-12-19 | 2019-12-19 | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
PCT/MX2020/000049 WO2021125930A1 (es) | 2019-12-19 | 2020-12-10 | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2019015589A MX2019015589A (es) | 2019-12-19 | 2019-12-19 | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019015589A true MX2019015589A (es) | 2021-06-21 |
Family
ID=76478449
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019015589A MX2019015589A (es) | 2019-12-19 | 2019-12-19 | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
Country Status (2)
Country | Link |
---|---|
MX (1) | MX2019015589A (es) |
WO (1) | WO2021125930A1 (es) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1319139A (zh) * | 1998-09-23 | 2001-10-24 | 牛津生物医学(英国)有限公司 | 多聚核苷酸构建体及其应用 |
PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
AU2008307643B9 (en) * | 2007-09-28 | 2014-04-17 | Intrexon Corporation | Therapeutic gene-switch constructs and bioreactors for the expression of biotherapeutic molecules, and uses thereof |
WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
-
2019
- 2019-12-19 MX MX2019015589A patent/MX2019015589A/es unknown
-
2020
- 2020-12-10 WO PCT/MX2020/000049 patent/WO2021125930A1/es active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2021125930A1 (es) | 2021-06-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021003554A (es) | Proteinas de union a dll3 y metodos de uso. | |
MX2021014007A (es) | Proteinas de union a epcam y metodos de uso. | |
WO2017077329A3 (en) | Nucleic acids, peptides and methods | |
MX2017014908A (es) | Proteinas de union triespecificas y metodos de uso. | |
MX2019009255A (es) | Proteínas quiméricas dirigidas y sus usos. | |
BRPI0410963A (pt) | anticorpo isolado ou porção biologicamente ativa deste, linhagem celular, composição farmacêutica, métodos de neutralizar uma atividade biológica de ctgf e de tratar ou prevenir um distúrbios associado com ctgf, anticorpo quimérico, medicamento, seqüência de polinucleotìdeos recombinante, e, célula hospedeira | |
BR112021025964A2 (pt) | Formas de sal de ácido bempedoico e métodos para uso das mesmas | |
BRPI0713000A8 (pt) | Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples | |
EA201200515A1 (ru) | Полипептиды и их применение | |
WO2011036442A3 (en) | Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders | |
MX2021007434A (es) | Peptidos de colageno producidos de forma sintetica y recombinante con eficacia biologica. | |
HRP20211191T1 (hr) | Bakterije oslabljene virulencije za tretiranje malignih solidnih tumora | |
MX2020008208A (es) | Agentes de unión a fibroblastos y uso de estos. | |
WO2014111458A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
MX2021014601A (es) | Proteinas recombinantes de union a fap y su uso. | |
MX2021001305A (es) | Anticuerpos anti-cxcr2 y usos de los mismos. | |
ZA202201827B (en) | Therapeutic fusion proteins | |
WO2016063026A3 (en) | Selective nav protein binders | |
EA202191208A1 (ru) | ВЕКТОРЫ, СОДЕРЖАЩИЕ AIMP2-DX2 И ЦЕЛЕВЫЕ НУКЛЕИНОВЫЕ КИСЛОТЫ ДЛЯ miR-142, И ИХ ПРИМЕНЕНИЕ | |
EA202290001A1 (ru) | Векторы aav с промотором миелинового белка ноль и их применение для лечения заболеваний, связанных со шванновскими клетками, таких как болезнь шарко-мари-тута | |
MX2019015589A (es) | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. | |
MY173174A (en) | Short bio-active peptides for promoting wound healing | |
WO2020142740A8 (en) | Treatment of sjogren's disease with nuclease fusion proteins | |
BR112013022557A2 (pt) | ligantes de peptídeo composições de polipeptídeo e métodos para uso dos mesmos | |
Barathiraja et al. | Expression and purification of biologically active bovine interferon λ3 (IL28B) in Pichia pastoris |